Fig. 3From: ATM splicing variants as biomarkers for low dose dexamethasone treatment of A-TFKBP5 and DUSP1 mRNA expression. Gene expression levels of the two evaluated prototypic targets. AT, untreated patients with AT n = 6; AT Dexa, patients with AT and treated with EryDex n = 10; WT, healthy volunteers n = 6. As predicted, in treated AT patients an improvement in gene expression was observedBack to article page